Polycythemia Vera – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Polycythemia Vera – Pipeline Review, H2 2017’, provides an overview of the Polycythemia Vera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera

The report reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects

The report assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Polycythemia Vera

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd

Galena Biopharma Inc

Gilead Sciences Inc

Italfarmaco SpA

Nerviano Medical Sciences Srl

PharmaEssentia Corp

Table of Contents

Table of Contents

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycythemia Vera - Overview

Polycythemia Vera - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Polycythemia Vera - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycythemia Vera - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd

Galena Biopharma Inc

Gilead Sciences Inc

Italfarmaco SpA

Nerviano Medical Sciences Srl

PharmaEssentia Corp

Polycythemia Vera - Drug Profiles

anagrelide hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idasanutlin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idelalisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropeginterferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycythemia Vera - Dormant Projects

Polycythemia Vera - Discontinued Products

Polycythemia Vera - Product Development Milestones

Featured News & Press Releases

Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid

Mar 14, 2017: AOP Orphan Pharmaceuticals announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera

Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016

Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation

Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan

May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012

May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases

Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition

Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera

Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera

Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Polycythemia Vera, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Polycythemia Vera – Pipeline by Bristol-Myers Squibb Company, H2 2017

Polycythemia Vera – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Polycythemia Vera – Pipeline by Galena Biopharma Inc, H2 2017

Polycythemia Vera – Pipeline by Gilead Sciences Inc, H2 2017

Polycythemia Vera – Pipeline by Italfarmaco SpA, H2 2017

Polycythemia Vera – Pipeline by Nerviano Medical Sciences Srl, H2 2017

Polycythemia Vera – Pipeline by PharmaEssentia Corp, H2 2017

Polycythemia Vera – Dormant Projects, H2 2017

Polycythemia Vera – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Polycythemia Vera, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports